JDRF Commends U.S. Representatives Reed, DeGette and Whitfield for Introducing Continuous Glucose Monitor (CGM) Coverage Legislation JDRF commends U.S. Representatives Tom Reed (R-NY), Diana DeGette (D-CO) and Ed Whitfield (R-KY) for introducing legislation, H.R. 5644, the ‘Medicare CGM Access Act of 2014,’ calling for continuous glucose monitor (CGM) coverage by Medicare. This legislation (which now […]
Chris Stiehl has lived with T1D for over 50 years and relies on his CGM for tight control. Since being diagnosed with type 1 diabetes (T1D) in 1961, Chris Stiehl has witnessed every innovation in care over the past 50 years. Yet, with all the great medical and technological advances he lives each day — like everyone with diabetes — […]
Study: Artificial pancreas systems with predictive low-glucose-suspend help reduce overnight hypoglycemia in individuals with type 1 diabetes Bedtime may soon be safer and a lot less anxiety filled for people with type 1 diabetes (T1D) thanks to software being developed as a next-step component for artificial pancreas systems. Called predictive low-glucose-suspend (pLGS), it interacts with […]
The technology on which many people rely for blood-glucose management?with all the tubes, infusion sets, and delicate circuitry?can really get in the way of executing proper yoga poses. For anyone who may have shied away from yoga for these reasons, take heart. Many people with T1D have mastered Monkey Pose and gone deep into Downward Dog—all while comfortably sporting an insulin pump.
A first-of-its-kind clinical pilot study has demonstrated the safety and feasibility of an artificial pancreas system in an outpatient, “real-world” setting. A second clinical study has shown that a hypoglycemia-hyperglycemia minimizer system can predict when blood-glucose levels are about to rise or fall and make appropriate adjustments in insulin delivery. These JDRF-supported studies represent critical steps on the path to a functional artificial pancreas for the benefit of people living with T1D.
JDRF-funded researchers have developed a formulation of liquid glucagon that remains stable and viable for long periods of time and thus may be usable in standard diabetes pumps. The research represents advancement toward the routine delivery of glucagon for people with T1D and may also facilitate the development of bihormonal closed-loop artificial pancreas systems.
JDRF has partnered with San Diego–based medical company Dexcom, Inc. to support the manufacture of a so-called smart transmitter prototype, which will be available for research purposes before it will be commercially available. The technological advance not only would reduce the number of devices a person would have to wear with an artificial pancreas system, but would also enable wireless connectivity among these devices—an important feature that would give people with T1D the freedom of movement while participating in real-life outpatient studies.
Countdown is written and produced by our Marketing and Communications team here at JDRF. As the leader of the team and JDRF’s chief marketing officer, I am pleased to bring our new issue to you. We have so much news and information to share—and it is our hope that you will share it with everyone you […]
People with type 1 diabetes (T1D) are often told “no.” We hear the long list of things we shouldn’t eat, and shouldn’t do, and shouldn’t even think about trying. For things outside of managing my T1D, I subscribe to the concept of “asking forgiveness, not permission.” (Like when I pierced my belly button when I […]
By Michelle A. Cissell, Ph.D. Women know the importance of taking extra care of themselves before and during pregnancy—for the optimal health of their babies, as well as for their own well-being. For women with type 1 diabetes (T1D), diligent self-management both before and during pregnancy is especially crucial, as high blood glucose levels increase […]